Search

Byline: Elpis Mantadakis (1), Victor M. Aquino (1), William R. Strand (2), R. Quigley (3) Keywords: Key wordsaBurkitt lymphoma; Renal failure (azotemia); Tumor lysis syndrome; Acute urinary obstruction Abstract: aAcute renal failure in Burkitt lymphoma is commonly the result of tumor lysis syndrome. We present a 15-year-old boy who developed hypertension, seizures, and acute renal failure due to extrinsic compression of the bladder and ureters by a large retrovesical Burkitt lymphoma. The causes of acute renal failure in Burkitt lymphoma and the incidence of acute urinary obstruction in this disease are reviewed. Author Affiliation: (1) Department of Pediatrics, Division of Hematology/Oncology, UT Southwestern Medical Center at Dallas and Children's Medical Center of Dallas, Dallas, Texas, USA, US (2) Department of Urology, UT Southwestern Medical Center of Dallas and Children's Medical Center of Dallas, Dallas, Texas, USA, US (3) Department of Pediatrics, Division of Nephrology, UT Southwestern Medical Center at Dallas and Children's Medical Center of Dallas, 5323 Harry Hines Boulevard, Dallas, TX 75235-9063, USA Tel.: +1-214-648-3438, Fax: +1-214-648-2034, US Article note: Received: 18 May 1998 / Revised: 30 June 1998 / Accepted: 1 July 1998

Byline: M. G. Seikaly (1), R. Quigley (1), M. Baum (1) Keywords: KeywordsaX-linked hypophosphatemia; Dipyridamole; Children Abstract: X-linked hypophosphatemia (XLH) is characterized clinically by rickets, hypophosphatemia and hyperphosphaturia. Conventional treatment of XLH with oral phosphate and vitamin D is associated with hypercalcuria and nephrocalcinosis. Recently, intravenous and oral dipyridamole has been reported to decrease fractional excretion of phosphate in adults with idiopathic hyperphosphaturia. Our objective was to determine whether oral dipyridamole therapy reduces urinary phosphate excretion and increases serum phosphate concentration in children with XLH. A prospective study was performed in six children with XLH. The average age of the patients at the start of the study was 12.5+-1.0 years. The effects of 12 weeks of oral dipyridamole therapy, at 4.4+-0.4 mg/kg body weight per day, on serum phosphorous, parathyroid hormone (PTH), 1,25 (O[H).sub.2 ]vitamin D, osteocalcin, tubular maximum for phosphate reabsorption (TmP/GFR), urinary calcium excretion, and cyclic adenosine 3',5'-monophosphate (cAMP) excretion, were compared to baseline levels. Our results show that there was no change in serum phosphorous concentration or TmP/GFR after 12 weeks of dipyridamole therapy. Dipyridamole therapy also had no effect on serum PTH, serum 1,25 (O[H).sub.2 ]vitamin D, alkaline phosphatase, osteocalcin levels, urinary calcium or cAMP excretion. We therefore concluded that in children with XLH, a 12-week course of dipyridamole had no effect on serum phosphorous or its urinary excretion. Dipyridamole therapy is unlikely to improve the bone disease in children with XLH. Author Affiliation: (1) University of Texas Southwestern Medical Center of Dallas and Texas Scottish Rite Hospital for Children, 5323 Harry Hines Blvd., Dallas, TX 75390-9063, USA e-mail: mseika@childmed.dallas.tx.us Tel.: +1-214-456-6005, Fax +1-214-456-6456, US Article note: Received: 7 February 2000 / Revised: 5 May 2000 / Accepted: 16 May 2000